Axim Biotechnologies, Inc.

Common Stock SEC Reporting - Current
Verified Company Profile 1/26/2017
Contact Info
  • 18 E 50th St 5th Floor
  • New York, NY 10022

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2016 10-Q
CIK 0001514946
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc. 2010
Employees Not Available
Company Officers/Contacts
George E. Anastassov CEO, President
Robert Malasek CFO
Lekhram Changoer CTO
Philip A. Van Damme Chief Scientific Officer
Company Directors
George E. Anastassov Chairman
Lekhram Changoer
Philip A. Van Damme
Service Providers
Accounting/Auditing Firm
805 Third Avenue
Suite 902
New York, NY, 10022
United States
Securities Counsel
Phillip E. Koehnke, APC
PO Box 235472
Encinitas, CA, 92024
United States
Investor Relations Firm
102 Madison Avenue
12th Floor
New York, NY, 10016
United States
Company History
  • Formerly=Axim International Inc until 7-2014
AXIM Security Details
Share Structure
Market Value1 $593,322,783 a/o Mar 23, 2017
Authorized Shares 300,000,000 a/o Sep 30, 2016
Outstanding Shares 52,506,441 a/o Jan 23, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 35,206,500 a/o Jan 23, 2017
Par Value 0.0001
Shareholders of Record 49 a/o Jan 23, 2017
Short Selling Data
Short Interest 87,608 (-8.88%)
Feb 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security